The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alignment of patient-clinician perspectives in triple-negative breast cancer (TNBC).
 
Tariqa Ackbarali
No Relationships to Disclose
 
Chelsey Goins
No Relationships to Disclose
 
Stephanie Walker
No Relationships to Disclose
 
Sara Donahue
No Relationships to Disclose
 
Jennifer Witt
No Relationships to Disclose
 
Gregory A. Vidal
Employment - Novartis (I)
Stock and Other Ownership Interests - Veris Health
Consulting or Advisory Role - AstraZeneca; AstraZeneca/Daiichi Sankyo; bioTheranostics; Daiichi Sankyo/Astra Zeneca; Genentech; Gilead Sciences; Lilly; Merck; Myriad Genetics; Novartis; Pfizer; Puma Biotechnology; Seagen; Stemline Therapeutics
Speakers' Bureau - AstraZeneca; Lilly
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Celcuity; Daiichi Sankyo; EMD Serono; Genentech/Roche; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Lilly; Myriad Genetics; Natera; Puma Biotechnology; Tesaro
Travel, Accommodations, Expenses - AstraZeneca
 
Tiffany A. Traina
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Exact Sciences; G1 Therapeutics; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Hengrui Pharmaceutical; Merck; Pfizer; Stemline Therapeutics; Tersera
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Pfizer (Inst)